Press Release

Mar. 30, 2017Oncotelic and Autotelic Inc. Present to Present Data on OT-101 Program at 2017 American Association for Cancer Research Annual Meeting
Jan. 18, 2017Oncotelic and Autotelic Inc. Present Clinical Data at 2017 GI Cancer Symposium to Support IL-8 Positive Association with Survival Improved Overall Survival in Advanced Pancreatic Cancer treated with Trabedersen (OT-101)
Sept. 25-28, 2016Dr. Larn Hwang, CEO, will present the poster entitled 'Impact of Antisense OT-101 Therapy on the Cytokine and Chemokine Profile in Patients with Pancreatic Cancer' on September 26th, 2016 at the 12th Annual Meeting of the Oligonucleotide Therapeutics Society in Montreal, Canada.
Sept. 1-6, 2016Dr. Larn Hwang, CEO, will conduct oral presentation titled 'Cytokine Induction by Trabedersen (OT-101) Treatment - Results from a Phase I/II Trial in Pancreatic Cancer Patients' on September 4th, 2016 at the 43rd International Society of Oncology and Biomarkers (ISOBM) Congress in Chicago, IL.
Mar. 10-12, 2016Dr. Larn Hwang, CEO, will be presenting the poster entitled "Treatment with Trabedersen- an anti-TGF-beta-2 antisense- primed tumors to subsequent chemotherapies" at The 3rd St. Gallen International Gastrointestinal Cancer Conference, St. Gallen, Switzerland.
Feb. 19-21, 2016Li Huang, Sr. Scientist/Biostatistics, will be presenting the poster entitled “Synergistic anti-tumor activity of OT-101, a TGF- 2 inhibitor, and Dacarbazine against C8161 human melanoma xenograft in athymic nude mice" at The 10th Canadian Melanoma Conference, Whistler, British Columbia, Canada.
Oct. 14, 2015 (BUSINESS WIRE)--Isarna Therapeutics, the leader in transforming growth factor beta (TGF-β) isoform targeted antisense therapeutics, and Autotelic Inc., a specialist in therapeutic drug monitoring and development, today announced an asset sale and purchase agreement for trabedersen, Isarna’s TGF-β2 antisense oligonucleotide. Autotelic acquires full and worldwide rights to develop trabedersen, which had previously reached Phase 3 clinical evaluation to treat recurrent high-grade glioma. No financial details of the agreement have been disclosed.